Creon（Pancreatin Enteric-coated Capsules）

Phase 1Small molecule

Creon（Pancreatin Enteric-coated Capsules） is one of 37 small molecule programs targeting Chronic Pancreatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PancreatitisActive, not recruiting

Chronic PancreatitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

51 competitors in Chronic Pancreatitis

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

1 2

Creon

AbbVie

Approved

4 3

Marcaine

IInnocoll

Approved

—4

VIOKACE

DDigestive Care, Inc.

Phase 3

2 5

Kenalog

BBassett Healthcare

Phase 3

1 6

Actos

Takeda

Phase 2

2 7

Actemra

Roche

Phase 2

1 8

Thalomid

Bristol-Myers Squibb

Phase 2

1 9

Zocor

OOrganon and Co

Phase 2

2 10

Jardiance

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2035

Phase 1Recruiting

Chronic Pancreatitis

NCT07314489

Clinical

Trials by Indication[1]

Chronic Pancreatitis1 trial

A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis

Recruiting·SShanghai Changzheng Hospital·Phase 1·NCT07314489·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Creon（Pancreatin Enteric-coated Capsules）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Creon（Pancreatin Enteric-coated Capsules） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Creon（Pancreatin Enteric-coated Capsules）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Changzheng Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Changzheng Hospital

Creon（Pancreatin Enteric-coated Capsules）

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2035

Trials by Indication[1]

Chronic Pancreatitis1 trial

References

Drug Info

Quick Facts

Related News